Search Results - steven+rosenberg

23 Results

Sort By:

Chimeric Antigen Receptors that Recognize Mesothelin for Cancer Immunotherapy

Abstract: Chimeric antigen receptors (CARs) with high affinity for mesothelin that can be used as an immunotherapy to treat cancers that express mesothelin, such as pancreatic cancer, ovarian cancer, and mesothelioma. The technology includes CAR constructs with one of three different mesothelin-specific antibody portions, including either the mouse-derived...

Published: 4/8/2024 | Inventor(s): Steven Feldman, Steven Rosenberg, Ira Pastan

Keywords(s): CAR, Immunotherapy, MESOTHELIN, T-CELLS

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy

Abstract: Cyclin-dependent kinase inhibitor 2A gene, also known as CDKN2A, is a tumor suppressor gene and is commonly inactivated through somatic mutations in many human cancers. For example, inactivation of CDKN2A is highly prevalent in melanoma, gastrointestinal and pancreatic cancers. Through germline mutations, CDKN2A is associated with predisposition...

Published: 4/8/2024 | Inventor(s): Sri Krishna, Shoshana Levi, Paul Robbins, Steven Rosenberg, Shirley Nah, Rami Yoseph, Frank Lowery

Keywords(s): adoptive cell therapy, CDKN2A, cyclin dependent kinase inhibitor 2A, Immunotherapy, Krishna, MELANOMA, Neoantigen, Rosenberg, T Cell Receptor, TCR

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration

Human T Cell Receptors for Treating Cancer

Abstract: T cell receptors (TCRs) are proteins that recognize antigens in the context of infected or transformed cells and activate T cells to mediate an immune response and destroy abnormal cells. TCRs consist of two domains, one variable domain that recognizes the antigen and one constant region that helps the TCR anchor to the membrane and transmit...

Published: 4/8/2024 | Inventor(s): Richard Morgan, Nachimuthu Chinnasamy, Steven Rosenberg

Keywords(s): COLON CANCER, Hepatocellular cancer, MELANOMA, PROSTATE CANCER, SSX

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)

Abstract: Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize unique antigens expressed by cancer cells (“neoantigens”). Neoantigen specific TIL administration in patients has resulted in long term regression of certain metastatic cancers. However, one of the challenges of ACT and engineered T cell receptor (TCR) therapies...

Published: 4/8/2024 | Inventor(s): Sri Krishna, Paul Robbins, Rami Yoseph, James Yang, Kenichi Hanada, Frank Lowery, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptor, TCR, TIL, tumor, Tumor Infiltrating Lymphocyte

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

T Cell Receptors Targeting p53 Mutations for Cancer Immunotherapy and Adoptive Cell Therapy

Abstract: The tumor protein p53 is a cell cycle regulator. It responds to DNA damage by triggering the DNA repair pathway and allowing cell division to occur or inducing cell growth arrest, cellular senescence, and/or apoptosis. p53 therefore acts as a tumor suppressor by preventing uncontrolled cell division. However, mutations in p53 that impair...

Published: 4/8/2024 | Inventor(s): Drew Deniger, Parisa Malekzadeh, Winifred Lo, Rami Yoseph, Paul Robbins, Maria Parkhurst, Anna Pasetto, Yong-Chen Lu, Steven Rosenberg

Keywords(s): Immunotherapy, p53, Rosenberg, T Cell Receptor, TCR, Tumor Protein P53

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology

A Dendritic Cell Vaccine to Immunize Cancer Patients Against Mutated Neoantigens Expressed by the Autologous Cancer

Abstract: Vaccines against non-viral cancers target mainly differentiation antigens, cancer testis antigens, and overexpressed antigens. One common feature to these antigens is their presence in central immunological tolerance. Using these vaccines, T cells underwent depletion of high avidity clones directed against such antigens. This depletion can...

Published: 4/8/2024 | Inventor(s): Gal Cafri, Paul Robbins, Jared Gartner, Steven Rosenberg

Keywords(s): CANCER, Dendritic cells, Immunotherapy, Neoantigens, Rosenberg, T Cells, vaccines

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Vaccines

Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer

Abstract: Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy that utilizes autologous, antitumor T cells to attack tumors through recognition of tumor-specific mutations, or neoantigens. A major hurdle in the development of ACT is the exhausted phenotype exhibited by many neoantigen-specific T cells, which limits their efficacy...

Published: 4/8/2024 | Inventor(s): Sri Krishna, Zhiya Yu, Kenichi Hanada, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Krishna, Neoantigen, Rosenberg, T-Cell Receptor, TCR, Vaccine

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

T Cell Receptors Targeting KRAS Mutants for Cancer Immunotherapy/Adoptive Cell Therapy

Abstract: Mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) gene are among the most common oncogenic drivers in human cancers, affecting nearly a third of all solid tumors. Point mutations in the KRAS gene most frequently affect amino acid position 12, resulting in the substitution of the native glycine (G) residue for other amino...

Published: 4/8/2024 | Inventor(s): Eric Tran, Yong-Chen Lu, Paul Robbins, Steven Rosenberg, Anna Pasetto, Zhili Zheng

Keywords(s): CANCER, Immunotherapy, Mutated KRAS, Rosenberg, T-cell Receptors

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

T-Cell Therapy Against Patient-Specific Cancer Mutations

Abstract: Human cancers contain genetic mutations that are unique to each patient. Some of the mutated peptides are immunogenic, can be recognized by T cells, and therefore, may serve as therapeutic targets. Scientists at the National Cancer Institute's Surgery Branch developed a method to identify T cells that specifically recognize immunogenic mutations...

Published: 4/8/2024 | Inventor(s): Eric Tran, Yong-Chen Lu, Paul Robbins, Steven Rosenberg

Keywords(s): Cholangiocarcinoma, Immunogenic, Rosenberg, T-cell, Tran

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients

Abstract: Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize antigens expressed by cancer cells (neoantigens). Neoantigen specific TIL administration in patients has resulted in long-term regression of certain metastatic cancers. However, current procedures for TIL therapy are highly invasive, labor-intensive, and...

Published: 4/8/2024 | Inventor(s): Rami Yoseph, Paul Robbins, Frank Lowery, Sri Krishna, Amy Copeland, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptors, TCRs, TILS, Tumor Infiltrating Lymphocytes

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

1 2 3